secwatch.observer — SEC 8-K summary
======================================

Issuer:     SELLAS Life Sciences Group, Inc. (SLS)
CIK:        0001390478
Form:       8-K
Filed at:   2023-10-16T23:59:59+00:00
Accession:  0001104659-23-109256
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SELLAS reports positive Phase 2a topline data for SLS009 in AML; first patient achieved complete response
--------------------------------------------------------------------------------

- First of 5 enrolled r/r AML patients achieved complete response, remains alive in 5th month of treatment.
- All 5 patients alive at last follow-up; 4 continue treatment; anti-leukemic effects seen in all.
- No significant safety issues observed at 45 mg dose level; median OS for venetoclax-failure AML is ~2.5 months.
- SLS009 is first CDK9 inhibitor to achieve CR in combination with AZA/VEN in venetoclax-resistant AML.
- Topline data for 60 mg dose expected later this quarter; multiple registrational opportunities cited.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923109256/0001104659-23-109256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1390478/000110465923109256/tm2328502d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-109256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer